GlaxoSmithKline PLC (LON:GSK) target price held steady at 1,900.00GBX, reported today by Liberum Capital
- Updated: September 19, 2016
Stating a possible upside of 0.16%, Liberum Capital held the target stock price of GlaxoSmithKline PLC (LON:GSK) at 1,900GBX.
Just yesterday GlaxoSmithKline PLC (LON:GSK) traded 0.70% lower at 1,644.00GBX. The company’s 50-day average is 1,656.11GBX and its two hundred day average is 1,528.28GBX. With the last stock close up 6.92% from the two hundred day moving average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the date range. 1,326,118 shares of the stock traded hands, down from ann average trading volume of 8,772,160.
Recent Performance Chart:
With a market cap of 0.0 GBX, GlaxoSmithKline PLC has a 52 week low of 1,227.50GBX and a one-year high of 1,716.50GBX with a PE ratio of 2,723.
In addition to Liberum Capital reporting it’s target price, a total of 24 brokers have released a report on the company. The consensus target is 1,577.33GBX with three analysts rating the stock a strong buy, six firms rating the company a buy, 17 analyts rating the stock a hold, two analysts rating the stock to underperform, and lastly 0 analystsrating the stock as sell.
General Company Details For GlaxoSmithKline PLC (LON:GSK)
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, and respiratory and rare diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.